Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eisai Pays $78 Million to Acquire Small China Generic Drugmaker

publication date: Dec 2, 2015
Eisai Co. of Japan will expand its China operations by acquiring generic drugmaker Liaoning TianYi Biological Pharma for $78 million. TianYi has China approval for 90 products, including both chemical drugs and TCM products. It currently markets about 20 of these and also produces APIs. With the acquisition, Eisai enters the hyper-competitive generic drug business in China for the first time; its current product line consists entirely of patent-protected drugs. More details....

Stock Symbol: (TO: 4523)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital